221 related articles for article (PubMed ID: 33795127)
21. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of small-cell versus large-cell gastroenteropancreatic neuroendocrine carcinomas: A population-based study.
Abdel-Rahman O; Fazio N
J Neuroendocrinol; 2021 May; 33(5):e12971. PubMed ID: 33870570
[TBL] [Abstract][Full Text] [Related]
23. Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors.
Keck KJ; Maxwell JE; Menda Y; Bellizzi A; Dillon J; O'Dorisio TM; Howe JR
Surgery; 2017 Jan; 161(1):272-279. PubMed ID: 27863780
[TBL] [Abstract][Full Text] [Related]
24. [Pathological characteristics and survival analysis of 355 patients with gastroenteropancreatic neuroendocrine neoplasms].
Li Y; Wang YF; Tan BB; Er LM; Zhao Q; Fan LQ; Zhang ZD; Liu Y
Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):426-431. PubMed ID: 32482035
[No Abstract] [Full Text] [Related]
25. Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute.
Shin Y; Ha SY; Hyeon J; Lee B; Lee J; Jang KT; Kim KM; Park YS; Park CK
Cancer Res Treat; 2015 Oct; 47(4):738-46. PubMed ID: 25687852
[TBL] [Abstract][Full Text] [Related]
26. Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients.
Baeg K; Harris C; Naparst MS; Ahn E; Thapi S; Martin J; Rustgi S; Mhango G; Wisnivesky J; Kim MK
BMC Cancer; 2021 Feb; 21(1):146. PubMed ID: 33563241
[TBL] [Abstract][Full Text] [Related]
27. The importance of clinical information in patients with gastroenteropancreatic neuroendocrine tumor.
Kudo A; Akashi T; Kumagai J; Ban D; Inokuchi M; Kojima K; Kawano T; Tanaka S; Arii S
Hepatogastroenterology; 2012; 59(120):2450-3. PubMed ID: 22584507
[TBL] [Abstract][Full Text] [Related]
28. Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia.
Ptasnuka M; Ozolins A; Narbuts Z; Truskovs A; Sperga M; Plaudis H
World J Surg; 2020 Feb; 44(2):585-593. PubMed ID: 31605174
[TBL] [Abstract][Full Text] [Related]
29. Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors.
Lau SC; Abdel-Rahman O; Cheung WY
Med Oncol; 2018 Aug; 35(9):123. PubMed ID: 30078166
[TBL] [Abstract][Full Text] [Related]
30. An 11-year retrospective study: clinicopathological and survival analysis of gastro-entero-pancreatic neuroendocrine neoplasm.
Liu H; Xie R; Zhao Z; Xu D; Yang K; Ding M; Tan D; Liao W; Han X; Zhang J; Shen D; Yuan J; Xu Z; Fei J
Medicine (Baltimore); 2020 Aug; 99(33):e21682. PubMed ID: 32872039
[TBL] [Abstract][Full Text] [Related]
31. Lymph Node Metastasis in the Prognosis of Gastroenteropancreatic Neuroendocrine Tumors.
Martin JA; Warner RRP; Aronson A; Wisnivesky JP; Kim MK
Pancreas; 2017 Oct; 46(9):1214-1218. PubMed ID: 28902794
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathologic Features of Gastroenteropancreatic Neuroendocrine Tumors: A Single-center Experience.
Akın Telli T; Esin E; Yalçın Ş
Balkan Med J; 2020 Aug; 37(5):281-286. PubMed ID: 32573179
[TBL] [Abstract][Full Text] [Related]
33. Primary Site Predicts Grade for Gastroenteropancreatic Neuroendocrine Tumors.
Fitzgerald TL; Mosquera C; Lea CS; McMullen M
Am Surg; 2017 Jul; 83(7):799-803. PubMed ID: 28738955
[TBL] [Abstract][Full Text] [Related]
34. Prognostic features of gastro-entero-pancreatic neuroendocrine neoplasms in primary and metastatic sites: Grade, mesenteric tumour deposits and emerging novelties.
Kankava K; Maisonneuve P; Mangogna A; Centonze G; Cattaneo L; Prinzi N; Pusceddu S; Fazio N; Pisa E; Di Domenico S; Bertani E; Mazzaferro V; Albertelli M; Grillo F; Milione M
J Neuroendocrinol; 2021 Aug; 33(8):e13000. PubMed ID: 34268808
[TBL] [Abstract][Full Text] [Related]
35. [Surgical treatments for gastroenteropancreatic neuroendocrine tumor (GEP-NET)].
Aoki T; Kokudo N
Nihon Shokakibyo Gakkai Zasshi; 2014 Dec; 111(12):2272-9. PubMed ID: 25482902
[No Abstract] [Full Text] [Related]
36. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival.
van Vilsteren FG; Baskin-Bey ES; Nagorney DM; Sanderson SO; Kremers WK; Rosen CB; Gores GJ; Hobday TJ
Liver Transpl; 2006 Mar; 12(3):448-56. PubMed ID: 16498656
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine tumors: analysis from a single-institution.
Zeng YJ; Liu L; Wu H; Lai W; Cao JZ; Xu HY; Wang J; Chu ZH
Asian Pac J Cancer Prev; 2013; 14(10):5775-81. PubMed ID: 24289577
[TBL] [Abstract][Full Text] [Related]
38. Duodenal, ampullary, and pancreatic neuroendocrine tumors: Oncologic outcomes are driven by tumor biology and tissue of origin.
Schmocker RK; Wright MJ; Ding D; Javed AA; Cameron JL; Lafaro K; Burns WR; He J; Wolfgang CL; Burkhart RA
J Surg Oncol; 2021 Feb; 123(2):416-424. PubMed ID: 33125737
[TBL] [Abstract][Full Text] [Related]
39. Interaction of race and pathology for neuroendocrine tumors: Epidemiology, natural history, or racial disparity?
DePalo DK; Lee RM; Lopez-Aguiar AG; Gamboa AC; Rocha F; Poultsides G; Dillhoff M; Fields RC; Idrees K; Nathan H; Abbott D; Maithel SK; Russell MC;
J Surg Oncol; 2019 Nov; 120(6):919-925. PubMed ID: 31385621
[TBL] [Abstract][Full Text] [Related]
40. Cocoon formation in patients with midgut neuroendocrine tumors: a rare and unrecognized final pathway.
Wang YZ; King H; Diebold A
Pancreas; 2013 Aug; 42(6):944-8. PubMed ID: 23587852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
